Processa Pharmaceuticals Future Growth

Future criteria checks 0/6

Processa Pharmaceuticals is forecast to grow earnings and revenue by 36.9% and 63.8% per annum respectively while EPS is expected to grow by 40.2% per annum.

Key information

36.9%

Earnings growth rate

40.2%

EPS growth rate

Pharmaceuticals earnings growth	22.8%
Revenue growth rate	63.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20

Earnings and Revenue Growth Forecasts

NasdaqCM:PCSA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	20	-15	N/A	N/A	2
12/31/2025	N/A	-14	N/A	-12	2
12/31/2024	N/A	-13	N/A	-8	2
12/31/2023	N/A	-11	-8	-8	N/A
9/30/2023	N/A	-22	-8	-8	N/A
6/30/2023	N/A	-26	-10	-10	N/A
3/31/2023	N/A	-28	-10	-10	N/A
12/31/2022	N/A	-27	-10	-10	N/A
9/30/2022	N/A	-18	-10	-10	N/A
6/30/2022	N/A	-15	-8	-8	N/A
3/31/2022	N/A	-13	-8	-8	N/A
12/31/2021	N/A	-11	-9	-9	N/A
9/30/2021	N/A	-23	-8	-8	N/A
6/30/2021	N/A	-23	-7	-7	N/A
3/31/2021	N/A	-20	-5	-5	N/A
12/31/2020	N/A	-19	-3	-3	N/A
9/30/2020	N/A	-6	-1	-1	N/A
6/30/2020	N/A	-4	-2	-2	N/A
3/31/2020	N/A	-4	-3	-3	N/A
12/31/2019	N/A	-4	-3	-3	N/A
9/30/2019	N/A	-3	-3	-3	N/A
6/30/2019	N/A	-3	-3	-3	N/A
3/31/2019	N/A	-3	-3	-3	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-4	-4	-4	N/A
6/30/2018	N/A	-4	-4	-4	N/A
3/31/2018	N/A	-3	-3	-3	N/A
12/31/2017	N/A	-2	-2	-2	N/A
12/31/2016	N/A	-2	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCSA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PCSA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PCSA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PCSA is forecast to have no revenue next year.

High Growth Revenue: PCSA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PCSA's Return on Equity is forecast to be high in 3 years time

Processa Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$15.00

Recent updates

Processa Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2024

Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research

Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial

New major risk - Shareholder dilution

Co-Founder recently bought US$51k worth of stock

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Processa Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14.35 million.

Processa Pharmaceuticals, Inc. Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety over Capecitabine

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals, Inc. Provides Data Update Supporting A Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals, Inc. Appoints George Ng as Chief Executive Officer

New major risk - Share price stability

New major risk - Market cap size

Processa Pharmaceuticals, Inc. Announces to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Positive Gastric Emptying Results from its Pcs12852 Phase 2A Trial in Patients

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals, Inc. Provides Update on Enrollment Across All Clinical Programs

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

High number of new and inexperienced directors

Processa Pharmaceuticals, Inc. Announces Board Changes

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Processa Pharmaceuticals, Inc., Annual General Meeting, Jul 11, 2022

Price target decreased to US$15.00

Processa Pharmaceuticals, Inc. Doses First Patient in Amended Phase 1B Protocol for Pcs6422 Combined with Capecitabine

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

Co-Founder recently bought US$77k worth of stock

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals, Inc. announced that it has received $10.238773 million in funding

New 90-day high: US$10.89

Processa Pharmaceuticals, Inc. announced that it expects to receive $10.238773 million in funding

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Processa Pharmaceuticals, Inc. Announces Executive Changes

Processa Pharmaceuticals, Inc. Appoints R. Michael Floyd as Chief Operating Officer

Co-Founder recently bought US$125k worth of stock

Processa Pharmaceuticals, Inc. has completed an IPO in the amount of $19.2 million.

New 90-day low: US$3.95

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies